These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25627172)

  • 1. Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Huleatt PB; Khoo ML; Chua YY; Tan TW; Liew RS; Balogh B; Deme R; Gölöncsér F; Magyar K; Sheela DP; Ho HK; Sperlágh B; Mátyus P; Chai CL
    J Med Chem; 2015 Feb; 58(3):1400-19. PubMed ID: 25627172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
    Wang Z; Wu J; Yang X; Cai P; Liu Q; Wang KDG; Kong L; Wang X
    Bioorg Med Chem; 2016 Nov; 24(22):5929-5940. PubMed ID: 27692996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
    Zindo FT; Barber QR; Joubert J; Bergh JJ; Petzer JP; Malan SF
    Eur J Med Chem; 2014 Jun; 80():122-34. PubMed ID: 24769350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
    Jenner P
    Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R; Lecht S; Lazarovici P
    Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: Synthesis, biological evaluation and docking study.
    Krátký M; Vu QA; Štěpánková Š; Maruca A; Silva TB; Ambrož M; Pflégr V; Rocca R; Svrčková K; Alcaro S; Borges F; Vinšová J
    Bioorg Chem; 2021 Nov; 116():105301. PubMed ID: 34492558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
    Yang HL; Cai P; Liu QH; Yang XL; Li F; Wang J; Wu JJ; Wang XB; Kong LY
    Eur J Med Chem; 2017 Sep; 138():715-728. PubMed ID: 28728104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
    Tao D; Wang Y; Bao XQ; Yang BB; Gao F; Wang L; Zhang D; Li L
    Eur J Med Chem; 2019 Jul; 173():203-212. PubMed ID: 31005056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action.
    Elkamhawy A; Kim HJ; Elsherbeny MH; Paik S; Park JH; Gotina L; Abdellattif MH; Gouda NA; Cho J; Lee K; Nim Pae A; Park KD; Roh EJ
    Bioorg Chem; 2021 Nov; 116():105352. PubMed ID: 34562673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
    Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
    Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M; Maruyama W
    Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
    Xu YX; Wang H; Li XK; Dong SN; Liu WW; Gong Q; Wang TD; Tang Y; Zhu J; Li J; Zhang HY; Mao F
    Eur J Med Chem; 2018 Jan; 143():33-47. PubMed ID: 29172081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
    Unzeta M; Sanz E
    Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity.
    Yu PH; Davis BA; Boulton AA
    Biochem Pharmacol; 1993 Aug; 46(4):753-7. PubMed ID: 8363648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.
    Tatton W; Chalmers-Redman R; Tatton N
    J Neural Transm (Vienna); 2003 May; 110(5):509-15. PubMed ID: 12721812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
    Chavarria D; Fernandes C; Silva V; Silva C; Gil-Martins E; Soares P; Silva T; Silva R; Remião F; Oliveira PJ; Borges F
    Eur J Med Chem; 2020 Jan; 185():111770. PubMed ID: 31711793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
    Pretorius J; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
    Bioorg Med Chem; 2008 Sep; 16(18):8676-84. PubMed ID: 18723354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.